FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

Source Summary

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the ...